Abstract library

43 results for "racGAP1".
#1596 Triple Tracer Imaging Approach for the Non-Invasive Assessment of Chemokine Receptor 4 Expression in Gastroenteropancreatic Neuroendocrine Tumors
Introduction: The theranostic twins [68Ga]Pentixafor and [177Lu]Pentixather for chemokine-directed endoradiotherapy (ERT) were recently developed.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Rudolf Werner
Authors: Werner R, Weich A, Higuchi T, Schmid J, ...
#580 Diagnostic Performance of Dual Tracer PET/CT in Staging Neuroendocrine Tumors of the Lung
Introduction: Different positron emission tomography/computed tomography (PET/CT) tracers may be useful in staging lung neuroendocrine tumors (LNETs)
Conference:
Category: Clinical
Presenting Author: Dr. Giorgio Treglia
#143 Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors
Introduction: In the absence of preoperative somatostatin receptor (sst) scans, knowledge of immunohistochemical sst2 tumor expression may help in predicting the success of somatostatin analogue-based follow-up studies and treatment of neuroendocrine tumors (NETs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Karsten Müssig
#293 99mTc Labelled GLP-1 Scintigraphy with Use of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-Exendin-4 in the Diagnosis of Insulinoma
Introduction: GLP-1-receptor scanning offers a new approach for successful localization of small insulinomas or those that are undetectable by other methods.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Anna Sowa-Staszczak
#401 Status of DNA Repair and Cell Proliferation Markers in High Grade Neuroendocrine Carcinoma of the Uterine Cervix (cNEC) Compared to Small Cell Carcinoma of the Lung (SCLC)
Introduction: Most patients (pts) with cNEC are treated with chemotherapy regimens used for SCLC due to both tumors’ histological similarity and aggressive behavior.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Boris Naraev
#540 Diagnositc and Prognostic Role of 68GA-DOTATATE PET in Patients with Neuroendocrine Tumors
Introduction: Octreoscan (OS) is currently the gold standard for diagnosis of somatostatin receptor positive NET but it is limited by a lower spatial resolution and physiological uptake noises. DOTATATE is a somatostatin analogue, radiolabelled with 68Ga and adapted for PET imaging.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: DR Francesca Marciello
#705 A Multi-Center Retrospective Evaluation of Neuroendocrine Tumors (Anatolian Society of Medical Oncology Group Study)
Introduction: Neuroendocrine tumors (NETs) are uncommon malignancies.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: M.D Halit Karaca
Authors: Karaca H, Erol O, Ulas A, Demirci U, ...
#864 Diagnostic and Outcome Differences between Sporadic and Familial Cases of Medullary Thyroid Cancer: A Retrospective Cohort Study
Introduction: Hereditary Medullary Thyroid Cancer (MTC) accounts for 20-30% of cases and has some clinically relevant peculiarities.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Guillermo Ropero Luis
#865 Diagnostic and Outcome Differences between Sporadic and Familial Cases of Pheochromocytoma and Paraganglioma: A Retrospective Cohort Study
Introduction: Hereditary Pheochromocytomas (PCC) and Paragangliomas (PGL) account for 30-35% of cases and have some clinically relevant peculiarities.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Guillermo Ropero Luis
#888 Capecitabine (Cp) and Somatostatine Analog (SSA) Suitable Treatment for Progressing G1-G2 Neuroendocrine Tumors (WD NET)
Introduction: Results from phase II and non-randomized trials with metronomic 5-FU in combination with SSA in well-differentiated (WD) NET are limited, and considered investigational.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Riccardo Marconcini
Keywords: capecitabine